Telomir Pharmaceuticals (NASDAQ:TELO – Get Free Report) and Jaguar Animal Health (NASDAQ:JAGX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, earnings and profitability.
Valuation and Earnings
This table compares Telomir Pharmaceuticals and Jaguar Animal Health”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Telomir Pharmaceuticals | N/A | N/A | -$10.41 million | ($0.33) | -3.85 |
| Jaguar Animal Health | $11.69 million | 0.13 | -$38.49 million | ($33.24) | -0.01 |
Analyst Recommendations
This is a breakdown of recent ratings for Telomir Pharmaceuticals and Jaguar Animal Health, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Telomir Pharmaceuticals | 1 | 1 | 1 | 0 | 2.00 |
| Jaguar Animal Health | 1 | 0 | 1 | 0 | 2.00 |
Jaguar Animal Health has a consensus target price of $60.00, indicating a potential upside of 14,900.00%. Given Jaguar Animal Health’s higher possible upside, analysts plainly believe Jaguar Animal Health is more favorable than Telomir Pharmaceuticals.
Profitability
This table compares Telomir Pharmaceuticals and Jaguar Animal Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Telomir Pharmaceuticals | N/A | -315.26% | -259.29% |
| Jaguar Animal Health | -341.90% | -1,194.94% | -80.16% |
Institutional & Insider Ownership
12.0% of Jaguar Animal Health shares are held by institutional investors. 7.5% of Jaguar Animal Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Volatility & Risk
Telomir Pharmaceuticals has a beta of -0.73, suggesting that its stock price is 173% less volatile than the S&P 500. Comparatively, Jaguar Animal Health has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500.
Summary
Jaguar Animal Health beats Telomir Pharmaceuticals on 7 of the 11 factors compared between the two stocks.
About Telomir Pharmaceuticals
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.
About Jaguar Animal Health
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
Receive News & Ratings for Telomir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telomir Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
